Navigation Links
ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical,Model

KOS, Greece--(BUSINESS WIRE)--Jun 26, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases, today announced results demonstrating that ACE-011, a novel anabolic bone agent for the treatment of bone loss, preserved bone mass and architecture in a murine model of multiple myeloma. Multiple myeloma is a malignancy of plasma cells in the bone marrow that disrupts normal bone marrow function resulting in fractures, vertebral compressions and bone pain. The data were presented today at the 11th International Myeloma Workshop in Kos, Greece.

"The positive results from this study support the growing body of evidence that ACE-011 is a novel bone anabolic agent and may be the first anabolic agent for the treatment of cancer-related bone loss in diseases such as multiple myeloma", said Jasbir Seehra, Ph.D., Chief Scientific Officer at Acceleron.

In the study conducted by Professor Peter Croucher, Ph.D. at the University of Sheffield (UK), mice treated with ACE-011 maintained their bone mass, while untreated mice developed substantial bone loss as a result of the myeloma. Histomorphometry analysis revealed that mice treated with ACE-011 had normal bone formation parameters, while untreated mice had reduced bone formation and increased bone resorption. Furthermore, ACE-011 preserved the number of osteoblasts, the cells responsible for forming new bone, compared to untreated mice which lost these vital bone-forming cells.

"Anti-resorptive agents are current standard of care for multiple myeloma patients yet significant unmet medical need remains as patients continue to experience serious clinical complications such as bone pain and fractures", said Matthew L. Sherman, M.D., Chief Medical Officer at Acceleron. "We are excited by the encouraging results in this preclinical model of multiple myeloma as we prep are for a phase 2 clinical trial in multiple myeloma later this year".

Acceleron is developing therapeutics that addresses the clinical consequences of cancer, such as bone loss and/or muscle loss, as well as treatments that directly target the underlying tumor. Given the improving therapeutic outcomes leading to more cancer patients living longer with their disease, the frequency of secondary consequences of cancer is increasing.

About ACE-011

ACE-011, a novel bone anabolic agent currently in a phase 1 clinical trial, is a protein therapeutic based on the activin receptor IIA. In numerous preclinical models of bone loss, ACE-011 has demonstrated beneficial effects on both trabecular and cortical bone. ACE-011 increased bone mineral density, improved bone architecture, increased the mineral apposition and bone formation rates and improved bone mechanical strength. These effects have been demonstrated in therapeutic models of bone loss in which ACE-011 has stimulated bone formation - a significant unmet medical need that is underserved by current treatments for bone loss.

About Multiple Myeloma

Multiple myeloma is a malignancy of plasma cells in the bone marrow that disrupts normal bone marrow function. Myeloma cells invade and destroy the bone surrounding the marrow cavity leading to rapid and widespread osteoporosis and osteolytic bone lesions, resulting in fractures, vertebral compressions and bone pain. Intravenous bisphosphonates are the current standard of care, but significant unmet medical need remains since most patients will still have serious bone complications despite treatment. According to the International Myeloma Foundation, there are an estimated 750,000 people worldwide multiple myeloma. In the US and EU, there are approximately 80,000 myeloma patients whose disease has affected their bones.

About Acceleron Pharma

Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron's scientific approach takes advantage of its unique insight on the regenerative powers of two protein families: the Growth and Differentiation Factors (GDFs) and Bone Morphogenetic Proteins (BMPs). ACE-011, an anabolic bone agent, is the company's lead program, and is being developed to reverse bone loss in diseases such as cancer-related bone loss and osteoporosis. In addition, the company is advancing through preclinical development with product candidates that increase muscle mass, control angiogenesis and inhibit fat accumulation. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company's internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron are Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures, Sutter Hill Ventures and Venrock.

Contact

Acceleron Pharma
Steven Ertel, 617-520-1334
Vice President, Corporate Development
or
Media:
Suda Communications
Paul Kidwell, 617-296-3854


'"/>




Related medicine technology :

1. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
2. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
3. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
4. Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
5. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
6. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
7. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
8. First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder
9. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
10. Once Daily, Extended-Release Ropinirole Improves Parkinsons Symptoms in Patients not Optimally Controlled With Levodopa
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
(Date:4/19/2017)... SAN DIEGO , April 19, 2017 /PRNewswire/ ... ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new ... today announced the closing of its previously announced ... common stock at a public offering price of ... commissions and estimated offering expenses payable by Sorrento.  ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
Breaking Medicine Technology:
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... human performance, is proud to announce that it has received 510(k) clearance from ... the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling ...
(Date:4/25/2017)... (PRWEB) , ... April 25, ... ... based in Newport Beach, California, committed to raising awareness for Duchenne muscular ... results from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial ...
(Date:4/25/2017)... BC (PRWEB) , ... April 25, 2017 , ... The ... from Richmond, BC, who live with dental fear and require sedation to receive dental ... at ease during various procedures, from hygienic cleanings to oral surgery, at their ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
(Date:4/25/2017)... Clara, CA (PRWEB) , ... April 25, 2017 ... ... announces the addition of predictive analytics to its patient care management module. Using ... compliance even before a patient has been initiated on continuous positive airway pressure ...
Breaking Medicine News(10 mins):